# Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

> **NCT00038623** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** Yttrium-ibritumomab (Zevalin)
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00038623
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2007-12
- **Final completion:** 2010-02
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2011-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038623, "Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00038623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*